Revenue segments as reported by the company.

Immunology

Hematologic Oncology

Aesthetics

Neuroscience

Eye Care

Women's Health

Other Key Products

All other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Acquired in-process research and development

Other operating expense

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

AbbVie

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

AbbVie surpasses Q4 earnings forecast, eyes growth amid challenges

AbbVie's strong performance in Q4 2022 exceeded expectations, driven by key products like SKYRIZI and RINVOQ. Despite challenges in revenue and HUMIRA erosion, the company is focused on innovation and growth opportunities. Strategic investments in R&D and BD aim to navigate market dynamics and drive future success.

AbbVie surpasses Q1 expectations, eyes international growth amid challenges

AbbVie's Q1 2023 performance exceeded expectations, driven by key product sales and strong international results. While facing challenges in the U.S. market and inflationary pressures, the company remains confident in its long-term growth prospects and strategic initiatives.

AbbVie surpasses Q2 expectations, eyes revenue growth opportunities

AbbVie's Q2 2023 earnings call highlighted strong financial performance, successful execution in key therapeutic areas, and a promising outlook for revenue growth. Despite challenges like biosimilar competition and market dynamics, the company remains confident in its ability to deliver value and maintain growth.

AbbVie exceeds Q3 expectations, focuses on pipeline growth strategies

AbbVie's strong Q3 performance driven by key products and growth platforms, with positive trial results.
Challenges in aesthetics sales and Medicare drug pricing program offset by long-term growth opportunities.
Confidence in pipeline assets and strategic focus on combination therapies for future growth.
Maintaining strong market positions and investing in transformative therapies for competitive advantage.

AbbVie exceeds Q4 expectations, eyes growth through strategic acquisitions

AbbVie's stellar performance in Q4 2023 showcased strong sales growth, successful pipeline advancements, and strategic acquisitions. While facing challenges such as pricing pressures and safety concerns, the company is well-positioned to capitalize on opportunities in expanding its portfolio and driving growth through innovation and strategic partnerships.

AbbVie exceeds Q1 expectations, raises full-year guidance on strong sales growth

AbbVie's Q1 performance exceeded expectations, with strong sales growth in key products. The company raised full-year guidance and remains confident in maintaining good access for its brands. Challenges in aesthetics sales and inventory management are being addressed for future growth.

AbbVie reports robust Q2 results and raises 2024 guidance

AbbVie's strong Q2 performance, raised guidance, and strategic acquisitions highlight its growth trajectory.
Despite near-term challenges, the company's focus on key growth areas positions it for long-term success.
Investments in innovation and market expansion underscore AbbVie's commitment to sustained growth.
Overall, AbbVie's performance in Q2 2024 reflects a resilient and forward-looking approach to business.

AbbVie reports strong Q3 performance, raises guidance and dividend

AbbVie's Q3 2024 performance showcased robust sales growth, increased dividend, and raised revenue guidance, reflecting financial strength and market leadership.
The company's focus on long-term sustainability through investments, acquisitions, and pipeline advancements highlights a commitment to innovation and growth.
While facing challenges in clinical trial management and market competition, AbbVie remains well-positioned to leverage opportunities in diverse therapeutic areas for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

REGENXBIO

AbbVie (ABBV) is set to co-develop Regenexbio's investigational gene therapy for chronic retinal diseases like wet age-related macular degeneration.

AbbVie (ABBV) to Co-Develop Regenxbio Eye Disease Gene Therapy

REGENXBIO (RGNX) enters into a strategic partnership with AbbVie to co-develop and commercialize RGX-314, a potential gene therapy for retinal indications. Resultantly, REGENXBIO's share price surges.

REGENXBIO (RGNX) Stock Up on Collaboration Deal With AbbVie

AbbVie is a premier dividend stock with a superior and safe dividend. The business has been firing on all cylinders but a recent FDA decision likely spells trouble.

AbbVie: The FDA Decision On RINVOQ Likely Means Trouble

Bank of Nova Scotia

Chevron

Con Ed

Enterprise Products Partners

Magellan Midstream Partners

OGE Energy

Pinnacle West Capital

Verizon

This monthly series ranks a selection of dividend growth stocks in Dividend Radar and presents the ten top-ranked stocks for consideration. To rank stocks, I use DVK Quality Snapshots to obtain quality scores, sort them in descending order, and break ties with additional metrics.

10 Dividend Growth Stocks For September 2021

To expand its footprint in eye care, AbbVie Inc.( ABBV , Financial) has struck a billion-dollar deal to gain access to a gene therapy used to treat several common kinds of eye disease. The Chicago-area pharma giant announced Monday that it will be collaborating with Regenxbio Inc. ( RGNX , Financial) on the Maryland-based drugmaker's treatment called RGX-314.

Eyes Have It in AbbVie Deal With Regenxbio

AbbVie will pay Regenxbio up to $1.8 billion for a share of the potential profits from sales of the company's experimental gene therapy to treat a variety of eye diseases.

Regenxbio Stock Soars on AbbVie Eye Therapy Partnership

AbbVie Inc (NYSE: ABBV) and Regenxbio Inc (NASDAQ: RGNX) have partnered to develop and commercialize RGX-314, potential one-time gene therapy for wet age-related macular degeneration (wet AMD), diabetic retinopathy (DR), and other chronic retinal diseases.  RGX-314 is currently being evaluated in patients with wet AMD in a pivotal trial utilizing subretinal delivery and patients with wet AMD and DR in two separate Phase 2 trials using in-office suprachoroidal delivery.

AbbVie, RegenXBio Ink $1.75B Retinal Gene Therapy Collaboration

Shares of AbbVie Inc. ABBV, -0.55% were up 0.8% in premarket trading on Monday after the drug maker announced a potential billion-dollar deal to develop and commercialize Regenxbio Inc.'s RGNX, -1.66% experimental gene therapy, which is being tested as a treatment for several eye diseases. Regenxbio's stock jumped 18.2% on the news.

AbbVie's deal to develop Regenxbio's investigational gene therapy could be worth $1.8 billion

AbbVie and REGENXBIO Announce Eye Care Collaboration

Dow Inc

Kinder Morgan

Lumen Technologies

Altria

SPDR Portfolio S&P 500 High Dividend ETF

Western Union

There are 80 companies in the S&P 500 High Dividend Index ETF. Here are seven dividend stocks to buy from this exchange-traded fund that yield at least 4%.

7 S&P 500 Dividend Stocks To Buy Yielding 4%

Pubmatic

Even with the market regularly setting new highs, it could pay to keep an eye on these potential winners.

3 Stocks to Watch in September

NORTH CHICAGO, Ill., Sept. 10, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that data from its robust neuroscience portfolio will be presented at the International Parkinson and Movement Disorder Society (MDS) Virtual Congress 2021, taking place September 17-22.

AbbVie to Highlight Its Leadership in Movement Disorders at the International Parkinson and Movement Disorder Society Virtual Congress 2021

The EC's approval of Rinvoq for moderate to severe eczema is another step in the right direction for the company.

Could This Label Expansion Be a Blockbuster for AbbVie's Shareholders?

Genmab - ADR

NORTH CHICAGO, Ill., and COPENHAGEN, Denmark, Sept, 9, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Genmab A/S (Nasdaq: GMAB) today announced The Lancet published the results of the dose escalation part of the Phase 1/2 EPCORE™ NHL-1 first-in-human (FIH) dose escalation and cohort expansion clinical trial evaluating safety and preliminary efficacy of the investigational therapy epcoritamab (DuoBody®-CD3xCD20) in patients with relapsed/refractory B-cell non-Hodgkin's lymphoma (B-NHL).

Clinical Trial of Investigational Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma (B-NHL) Published in The Lancet

NORTH CHICAGO, Ill., Sept. 8, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that data from its migraine portfolio will be presented at the International Headache Congress 2021, held jointly this year by the International Headache Society and the European Headache Federation, from September 8-12.

AbbVie to Present Data From Its Migraine Portfolio at the 2021 International Headache Congress

The stock price of AbbVie reached its 52-week high of around $121 just last week before a recent sell-off in ABBV stock, especially after the U.S. FDA stated that all janus kinase inhibitors approved for arthritis treatment should carry a heart-risk warning on the label - sending the stock to lower.

Should You Buy AbbVie Stock After The Recent 7% Fall?

Caterpillar

CVS Health

Citizens & Northern

Deere & Company

Diversified Healthcare Trust

Eaton

General Dynamics

General Mills

Hormel Foods

Heritage Commerce

Illinois Tool Works

National Grid

Norfolk Southern

Norwood Financial

Realty Income Corp

Orrstown Financial

People's United Financial

Healthpeak Properties

Provident Financial Services

Procter & Gamble

Reynolds Consumer Products

Sabra Health Care

In August, my wife and I received a total of $1,307.71 of dividend income. We crossed one thousand dollars again in an off-month. Another strong month of dividend income, and the 4-digit mark is becoming more and more consistent. Despite the pandemic from COVID-19, dividend income continues to grow, due primarily to additional investment and reinvestment. During the month of August, my wife and I actually invested over $4,500+ into dividend-producing stocks!

Dividend Income Summary: Lanny's August 2021 Summary

The shares of AbbVie Inc (NYSE: ABBV) have received a $131 price target by Mizuho Securities. These are the details.

ABBV Stock: $131 Price Target By Mizuho Securities

Walgreens

Exxon Mobil

While summer officially ends on September 22, the Labor Day weekend marks the end for traders and investors, as Wall Street looks to return to normal and get back to work next week.

Why 5 of the Highest-Yielding Dividend Aristocrats May Be the Safest Bet for Rest of 2021

Baxter

Johnson & Johnson

Medtronic

UnitedHealth Group

Vertex Pharmaceuticals

Health Care Select Sector SPDR Fund

Covid-19 showed us how rapid advances in medicine and technology could create significant growth opportunities for healthcare stocks. The post 7 Healthcare Stocks to Buy Before $3.5 Trillion Floods In  appeared first on InvestorPlace.

7 Healthcare Stocks to Buy Before $3.5 Trillion Floods In

FDA requires a heart-risk warning on the label of AbbVie's (ABBV) JAK inhibitor medicine, Rinvoq.

AbbVie (ABBV) Stock Down as FDA Issues New Warning for Rinvoq

Eli Lilly

Pfizer

The FDA requires a heart-risk warning on the label of JAK inhibitor medicines, Pfizer's (PFE) Xeljanz/Xeljanz XR, Lilly (LLY)/Incyte's (INCY) Olumiant, and AbbVie's (ABBV) Rinvoq.

FDA Orders Warnings on Pfizer, Lilly, AbbVie JAK Drug Labels

News for AbbVie Stock (ABBV)